Dr. Chantelle Thomas

speaker

1,116 appearances 2 recordings 1 series first heard Jul 2026 last heard 30 Jul

Dr. Chantelle Thomas’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 2 in all, peaking in Jul 2026 with 2.

Appearances

newest first · ▶ plays the moment

RECOVERable: Mental Health and Addiction Experts Answer Your Questions · Psilocybin & Ibogaine: Can Psychedelics Cure Addiction? · 30 Jul 2026 podcast

Well, if we look at what's going to come up for the FDA, depression will come up first as the indication.

There's another sponsor called Compass Pathways that has been studying treatment-resistant depression, whereas the USONA sponsor has been looking at major depressive disorder.

So those are going to be the first two indications that will...

presumably go in front of the FDA for new drug application for the treatment of those conditions.

So depression has got more robust research behind it, but not too far behind that is psilocybin for nicotine use disorder and also psilocybin for alcohol use disorder.

I would say the opiate use disorder studies are a little further behind because there's not as many of them.

But that would be probably what's coming next down the pathway in terms of indications for psilocybin.

And then now there are actually some psilocybin trials for PTSD, which is also a first.

And some environments where they're looking at doing that in a group setting.

Actually, in New Mexico, there has been a regulation that's passed that allowed them to work in group settings with psilocybin.

And I think they're targeting PTSD populations.

Larry Lehman is a physician that's been involved with that work down there.

And another colleague of mine named Hanifa has also been involved in that work.

And it's kind of exciting to see what they're doing in New Mexico in terms of burgeoning trials with different indications and also looking at group and community settings as an opportunity for delivering care.

Yeah, so psilocybin is considered a classic psychedelic and that's due to its action on the serotonergic receptor sites.

And so we're seeing promising results in terms of it having a noteworthy signature, treatment signature for treating depression.

Oftentimes it's being compared to placebo therapy.

Or it's being compared, I think one of the other trials was looking at comparing it to an SSRI signature and how much of a difference might we see there.

An antidepressant.

Yes, exactly.

Showing 101–120 of 1,116 · page 6 of 56